Metraipolis › archive › dc_d1bebc04e170

EGFR-Targeted Nanoparticle Delivery of Osimertinib for Triple-Negative and Metastatic Breast Cancer Therapy — Europe PMC PMID:42797354

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42797354
DOI
10.3390/pharmaceutics18091179
License (as archived)
solo-consultazione
Archived
2026-10-08T03:49:32.059Z
SHA-256 of the archived text
e38852a76b979a34c762e50118e490b1375026ecb6a5fa1efe493ce9616bf0e3
Stable URL of this page
https://metraipolis.com/documento/dc_d1bebc04e170

How to cite

EGFR-Targeted Nanoparticle Delivery of Osimertinib for Triple-Negative and Metastatic Breast Cancer Therapy — Europe PMC PMID:42797354 — Europe PMC (en), https://europepmc.org/article/MED/42797354 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_d1bebc04e170 (Metraipolis archive dc_d1bebc04e170, sha256 e38852a76b979a34c762e50118e490b1375026ecb6a5fa1efe493ce9616bf0e3)
BibTeX
@misc{dcd1bebc04e170,
  title = {EGFR-Targeted Nanoparticle Delivery of Osimertinib for Triple-Negative and Metastatic Breast Cancer Therapy — Europe PMC PMID:42797354},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42797354},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_d1bebc04e170; sha256 e38852a76b979a34c762e50118e490b1375026ecb6a5fa1efe493ce9616bf0e3},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42797354. Agents can read the archived copy with the MCP tool read_document.